Correction: Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients

Arch Dermatol Res. 2025 Mar 12;317(1):546. doi: 10.1007/s00403-025-04136-8.

¹ Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Choung.rokson@mayo.edu.
² Division of Gastroenterology and Hepatology, 200 1st Street SW, Rochester, MN, 55905, USA. Choung.rokson@mayo.edu.
³ Inflammation and Immunology Research Unit, Pfizer R&D, Cambridge, MA, USA.
⁴ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
⁵ Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁶ Division of Gastroenterology and Hepatology, 200 1st Street SW, Rochester, MN, 55905, USA. murray.joseph@mayo.edu.

No abstract available

Publication types